Last reviewed · How we verify

Gemigliptin and/or Rosuvastatin

LG Life Sciences · Phase 3 active Small molecule

Gemigliptin and/or Rosuvastatin is a DPP-4 inhibitor and HMG-CoA reductase inhibitor (statin) Small molecule drug developed by LG Life Sciences. It is currently in Phase 3 development for Type 2 diabetes mellitus with dyslipidemia.

Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while rosuvastatin inhibits HMG-CoA reductase to lower cholesterol.

Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while rosuvastatin inhibits HMG-CoA reductase to lower cholesterol. Used for Type 2 diabetes mellitus with dyslipidemia.

At a glance

Generic nameGemigliptin and/or Rosuvastatin
SponsorLG Life Sciences
Drug classDPP-4 inhibitor and HMG-CoA reductase inhibitor (statin)
TargetDPP-4 and HMG-CoA reductase
ModalitySmall molecule
Therapeutic areaDiabetes and Cardiovascular
PhasePhase 3

Mechanism of action

This is a fixed-dose combination where gemigliptin enhances insulin secretion and reduces glucagon by preventing the degradation of GLP-1 and GIP, addressing hyperglycemia in type 2 diabetes. Rosuvastatin simultaneously reduces LDL cholesterol and cardiovascular risk by inhibiting the rate-limiting enzyme in cholesterol synthesis. The combination addresses both glycemic and lipid management in patients with type 2 diabetes and dyslipidemia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Gemigliptin and/or Rosuvastatin

What is Gemigliptin and/or Rosuvastatin?

Gemigliptin and/or Rosuvastatin is a DPP-4 inhibitor and HMG-CoA reductase inhibitor (statin) drug developed by LG Life Sciences, indicated for Type 2 diabetes mellitus with dyslipidemia.

How does Gemigliptin and/or Rosuvastatin work?

Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and improve glycemic control, while rosuvastatin inhibits HMG-CoA reductase to lower cholesterol.

What is Gemigliptin and/or Rosuvastatin used for?

Gemigliptin and/or Rosuvastatin is indicated for Type 2 diabetes mellitus with dyslipidemia.

Who makes Gemigliptin and/or Rosuvastatin?

Gemigliptin and/or Rosuvastatin is developed by LG Life Sciences (see full LG Life Sciences pipeline at /company/lg-life-sciences).

What drug class is Gemigliptin and/or Rosuvastatin in?

Gemigliptin and/or Rosuvastatin belongs to the DPP-4 inhibitor and HMG-CoA reductase inhibitor (statin) class. See all DPP-4 inhibitor and HMG-CoA reductase inhibitor (statin) drugs at /class/dpp-4-inhibitor-and-hmg-coa-reductase-inhibitor-statin.

What development phase is Gemigliptin and/or Rosuvastatin in?

Gemigliptin and/or Rosuvastatin is in Phase 3.

What are the side effects of Gemigliptin and/or Rosuvastatin?

Common side effects of Gemigliptin and/or Rosuvastatin include Nasopharyngitis, Headache, Myalgia, Elevated liver enzymes, Hypoglycemia.

What does Gemigliptin and/or Rosuvastatin target?

Gemigliptin and/or Rosuvastatin targets DPP-4 and HMG-CoA reductase and is a DPP-4 inhibitor and HMG-CoA reductase inhibitor (statin).

Related